Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling

Maricel Gomez-Soler, Marina Petersen Gehring, Bernhard C. Lechtenberg, Elmer Zapata-Mercado, Kalina A Hristova, Elena B. Pasquale

Research output: Contribution to journalArticle

Abstract

The EPH receptor A2 (EphA2) tyrosine kinase plays an important role in a plethora of biological and disease processes, ranging from angiogenesis and cancer to inflammation and parasitic infections. EphA2 is therefore considered an important drug target. Two short peptides previously identified by phage display, named YSA and SWL, are widely used as EphA2-targeting agents owing to their high specificity for this receptor. However, these peptides have only modest (micromolar) potency. Lack of structural information on the binding interactions of YSA and SWL with the extracellular EphA2 ligand-binding domain (LBD) has for many years precluded structure-guided improvements. We now report the high-resolution (1.53-2.20 Å) crystal structures of the YSA peptide and several of its improved derivatives in complex with the EphA2 LBD, disclosing that YSA targets the ephrin-binding pocket of EphA2 and mimics binding features of the ephrin-A ligands. The structural information obtained enabled iterative peptide modifications conferring low nanomolar potency. Furthermore, contacts observed in the crystal structures shed light on how C-terminal features can convert YSA derivatives from antagonists to agonists that likely bivalently interact with two EphA2 molecules to promote receptor oligomerization, autophosphorylation, and downstream signaling. Consistent with this model, quantitative FRET measurements in live cells revealed that the peptide agonists promote the formation of EphA2 oligomeric assemblies. Our findings now enable rational strategies to differentially modify EphA2 signaling toward desired outcomes by using appropriately engineered peptides. Such peptides could be used as research tools to interrogate EphA2 function and to develop pharmacological leads.

Original languageEnglish (US)
Pages (from-to)8791-8805
Number of pages15
JournalJournal of Biological Chemistry
Volume294
Issue number22
DOIs
StatePublished - Jan 1 2019

Fingerprint

varespladib methyl
Ligands
Peptides
Ephrins
Crystal structure
Derivatives
Oligomerization
Bacteriophages
Protein-Tyrosine Kinases
Biological Phenomena
Parasitic Diseases
Receptor Protein-Tyrosine Kinases
Display devices
Pre-Eclampsia
Molecules
Pharmacology
Pharmaceutical Preparations
Inflammation
Research

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Gomez-Soler, M., Gehring, M. P., Lechtenberg, B. C., Zapata-Mercado, E., Hristova, K. A., & Pasquale, E. B. (2019). Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. Journal of Biological Chemistry, 294(22), 8791-8805. https://doi.org/10.1074/jbc.RA119.008213

Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. / Gomez-Soler, Maricel; Gehring, Marina Petersen; Lechtenberg, Bernhard C.; Zapata-Mercado, Elmer; Hristova, Kalina A; Pasquale, Elena B.

In: Journal of Biological Chemistry, Vol. 294, No. 22, 01.01.2019, p. 8791-8805.

Research output: Contribution to journalArticle

Gomez-Soler, M, Gehring, MP, Lechtenberg, BC, Zapata-Mercado, E, Hristova, KA & Pasquale, EB 2019, 'Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling', Journal of Biological Chemistry, vol. 294, no. 22, pp. 8791-8805. https://doi.org/10.1074/jbc.RA119.008213
Gomez-Soler, Maricel ; Gehring, Marina Petersen ; Lechtenberg, Bernhard C. ; Zapata-Mercado, Elmer ; Hristova, Kalina A ; Pasquale, Elena B. / Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. In: Journal of Biological Chemistry. 2019 ; Vol. 294, No. 22. pp. 8791-8805.
@article{061193f9e04043569d924d74fc804083,
title = "Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling",
abstract = "The EPH receptor A2 (EphA2) tyrosine kinase plays an important role in a plethora of biological and disease processes, ranging from angiogenesis and cancer to inflammation and parasitic infections. EphA2 is therefore considered an important drug target. Two short peptides previously identified by phage display, named YSA and SWL, are widely used as EphA2-targeting agents owing to their high specificity for this receptor. However, these peptides have only modest (micromolar) potency. Lack of structural information on the binding interactions of YSA and SWL with the extracellular EphA2 ligand-binding domain (LBD) has for many years precluded structure-guided improvements. We now report the high-resolution (1.53-2.20 {\AA}) crystal structures of the YSA peptide and several of its improved derivatives in complex with the EphA2 LBD, disclosing that YSA targets the ephrin-binding pocket of EphA2 and mimics binding features of the ephrin-A ligands. The structural information obtained enabled iterative peptide modifications conferring low nanomolar potency. Furthermore, contacts observed in the crystal structures shed light on how C-terminal features can convert YSA derivatives from antagonists to agonists that likely bivalently interact with two EphA2 molecules to promote receptor oligomerization, autophosphorylation, and downstream signaling. Consistent with this model, quantitative FRET measurements in live cells revealed that the peptide agonists promote the formation of EphA2 oligomeric assemblies. Our findings now enable rational strategies to differentially modify EphA2 signaling toward desired outcomes by using appropriately engineered peptides. Such peptides could be used as research tools to interrogate EphA2 function and to develop pharmacological leads.",
author = "Maricel Gomez-Soler and Gehring, {Marina Petersen} and Lechtenberg, {Bernhard C.} and Elmer Zapata-Mercado and Hristova, {Kalina A} and Pasquale, {Elena B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1074/jbc.RA119.008213",
language = "English (US)",
volume = "294",
pages = "8791--8805",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "22",

}

TY - JOUR

T1 - Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling

AU - Gomez-Soler, Maricel

AU - Gehring, Marina Petersen

AU - Lechtenberg, Bernhard C.

AU - Zapata-Mercado, Elmer

AU - Hristova, Kalina A

AU - Pasquale, Elena B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The EPH receptor A2 (EphA2) tyrosine kinase plays an important role in a plethora of biological and disease processes, ranging from angiogenesis and cancer to inflammation and parasitic infections. EphA2 is therefore considered an important drug target. Two short peptides previously identified by phage display, named YSA and SWL, are widely used as EphA2-targeting agents owing to their high specificity for this receptor. However, these peptides have only modest (micromolar) potency. Lack of structural information on the binding interactions of YSA and SWL with the extracellular EphA2 ligand-binding domain (LBD) has for many years precluded structure-guided improvements. We now report the high-resolution (1.53-2.20 Å) crystal structures of the YSA peptide and several of its improved derivatives in complex with the EphA2 LBD, disclosing that YSA targets the ephrin-binding pocket of EphA2 and mimics binding features of the ephrin-A ligands. The structural information obtained enabled iterative peptide modifications conferring low nanomolar potency. Furthermore, contacts observed in the crystal structures shed light on how C-terminal features can convert YSA derivatives from antagonists to agonists that likely bivalently interact with two EphA2 molecules to promote receptor oligomerization, autophosphorylation, and downstream signaling. Consistent with this model, quantitative FRET measurements in live cells revealed that the peptide agonists promote the formation of EphA2 oligomeric assemblies. Our findings now enable rational strategies to differentially modify EphA2 signaling toward desired outcomes by using appropriately engineered peptides. Such peptides could be used as research tools to interrogate EphA2 function and to develop pharmacological leads.

AB - The EPH receptor A2 (EphA2) tyrosine kinase plays an important role in a plethora of biological and disease processes, ranging from angiogenesis and cancer to inflammation and parasitic infections. EphA2 is therefore considered an important drug target. Two short peptides previously identified by phage display, named YSA and SWL, are widely used as EphA2-targeting agents owing to their high specificity for this receptor. However, these peptides have only modest (micromolar) potency. Lack of structural information on the binding interactions of YSA and SWL with the extracellular EphA2 ligand-binding domain (LBD) has for many years precluded structure-guided improvements. We now report the high-resolution (1.53-2.20 Å) crystal structures of the YSA peptide and several of its improved derivatives in complex with the EphA2 LBD, disclosing that YSA targets the ephrin-binding pocket of EphA2 and mimics binding features of the ephrin-A ligands. The structural information obtained enabled iterative peptide modifications conferring low nanomolar potency. Furthermore, contacts observed in the crystal structures shed light on how C-terminal features can convert YSA derivatives from antagonists to agonists that likely bivalently interact with two EphA2 molecules to promote receptor oligomerization, autophosphorylation, and downstream signaling. Consistent with this model, quantitative FRET measurements in live cells revealed that the peptide agonists promote the formation of EphA2 oligomeric assemblies. Our findings now enable rational strategies to differentially modify EphA2 signaling toward desired outcomes by using appropriately engineered peptides. Such peptides could be used as research tools to interrogate EphA2 function and to develop pharmacological leads.

UR - http://www.scopus.com/inward/record.url?scp=85066967654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066967654&partnerID=8YFLogxK

U2 - 10.1074/jbc.RA119.008213

DO - 10.1074/jbc.RA119.008213

M3 - Article

C2 - 31015204

AN - SCOPUS:85066967654

VL - 294

SP - 8791

EP - 8805

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 22

ER -